Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 17/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CAPNS1 | P04632 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7514977 | 0.80 | CAPN1 (0.59) | CAPN1CAPNS1 | |
| SCHEMBL8812573 | 0.79 | CTSK (0.60) | CAPN1 | |
| SCHEMBL8812581 | 0.79 | CTSK (0.60) | CAPN1 | |
| SCHEMBL7516532 | 0.78 | CTSS (0.56) | CAPN1 | |
| SCHEMBL17852711 | 0.76 | ALDH1A1 (0.54) | CAPN1 | |
| SCHEMBL21006007 | 0.75 | CAPN1 (0.48) | CAPN1CYP1A2CAPNS1 | |
| SCHEMBL21880812 | 0.75 | EPHX2 (0.58) | CAPN1 | |
| SCHEMBL7514607 | 0.74 | CAPN1 (0.49) | CAPN1 | |
| SCHEMBL8810080 | 0.74 | CAPN1 (0.62) | CAPN1CYP1A2 | |
| SCHEMBL8810071 | 0.74 | CAPN1 (0.62) | CAPN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0641800-B1 | Lactol derivatives as inhibitors of cathepsin L | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-16 | — | — | EP | claimed |
| US-5496834-A | PEPTIDE DERIVATIVES AS CATHEPSIN L INHIBITORS AND INHIBITORS OF BONE RESORPTION OR TREATMENT OF OSTEOPOROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-05 | — | — | US | claimed |
| EP-0641800-B1 | Lactol derivatives as inhibitors of cathepsin L | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-01-16 | — | — | EP | disclosed |